A1C medication is any prescription drug used to lower A1C, the three-month average of blood glucose, in people with diabetes or high-risk prediabetes. Metformin is the most common first-line option, reducing A1C by 1.0 to 1.5 percentage points. Newer agents like GLP-1 receptor agonists and SGLT-2 inhibitors lower A1C further and address weight, heart, and kidney risk at the same time.
When A1C Medication Is Needed
The American Diabetes Association sets an A1C goal of under 7.0 percent for most adults with type 2 diabetes and under 6.5 percent for younger, low-risk patients. Lifestyle alone brings many people there, especially when weight loss exceeds 5 to 7 percent. When it does not, or when A1C exceeds 9.0 percent at diagnosis, medication is added immediately. For prediabetes (A1C 5.7 to 6.4 percent), medication is optional and usually follows a trial of diet and exercise; see the A1C levels hub for thresholds.
Metformin: The First-Line Drug
Metformin reduces hepatic glucose production and improves insulin sensitivity. In trials it lowers A1C by 1.0 to 1.5 points and does not cause weight gain or hypoglycemia as monotherapy. GI side effects (nausea, loose stool) affect 20 to 30 percent of users but usually fade within two weeks; extended-release formulations help. It is inexpensive, safe long-term, and has some cardiovascular benefit. Almost every treatment guideline places metformin first.
GLP-1 Receptor Agonists
Glucagon-like peptide 1 agonists, including semaglutide (Ozempic, Rybelsus, Wegovy), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and tirzepatide (Mounjaro, Zepbound), stimulate insulin release only when glucose is high, slow gastric emptying, and reduce appetite. They lower A1C by 1.5 to 2.0 points (2.0 to 2.5 for tirzepatide) and drive weight loss of 10 to 20 percent. The 2016 LEADER trial showed liraglutide cut cardiovascular death, heart attack, and stroke by 13 percent. They are given by weekly injection (or daily pill for Rybelsus), cost 800-1,300 dollars a month without coverage, and most commonly cause nausea that fades with dose titration.
SGLT-2 Inhibitors
Sodium-glucose cotransporter 2 inhibitors, including empagliflozin (Jardiance), dapagliflozin (Farxiga), canagliflozin (Invokana), and ertugliflozin (Steglatro), prevent the kidneys from reabsorbing glucose, so it leaves in the urine. They lower A1C by 0.5 to 1.0 points and reduce heart failure hospitalization, cardiovascular death, and kidney decline in high-risk patients. Side effects include genital yeast infections, urinary tract infections, and a small risk of diabetic ketoacidosis even at near-normal glucose. Cost runs 500-700 dollars a month.
Other Oral Medications
| Class | Examples | A1C drop | Notable notes |
|---|---|---|---|
| Sulfonylureas | Glipizide, glimepiride | 1.0-1.5% | Cheap, risk of hypoglycemia, weight gain |
| DPP-4 inhibitors | Sitagliptin, linagliptin | 0.5-0.8% | Weight neutral, expensive |
| Thiazolidinediones | Pioglitazone | 0.5-1.4% | Weight gain, edema |
| Meglitinides | Repaglinide | 0.5-1.0% | Taken with each meal |
| Alpha-glucosidase inhibitors | Acarbose | 0.5-0.8% | GI side effects common |
Insulin
Insulin is the most powerful A1C-lowering agent and the one used when A1C is very high at diagnosis (above 10 percent with symptoms) or when other medications fail to reach goal. It comes as long-acting (glargine, detemir, degludec) for basal coverage and rapid-acting (lispro, aspart, glulisine) for meals. A correctly titrated regimen can drop A1C by 2 to 3 points. Side effects include hypoglycemia and weight gain. It requires injection and careful glucose monitoring.
Metformin for Prediabetes
The Diabetes Prevention Program randomized 3,234 adults with prediabetes to placebo, lifestyle intervention, or metformin. Metformin cut progression to type 2 diabetes by 31 percent over three years. The ADA now recommends considering metformin for prediabetes patients who are under 60, have BMI 35 or higher, or have a history of gestational diabetes. For broader context, review the prediabetes 101 hub.
How Doctors Choose
Clinicians match the medication to the patient. Overweight patient with coronary disease? A GLP-1 agonist with proven cardiovascular benefit. Heart failure or chronic kidney disease? An SGLT-2 inhibitor. Budget-limited uncomplicated type 2 diabetes? Metformin first, sulfonylurea second. A1C above 9 percent at diagnosis with symptoms? Metformin plus insulin. Kidney function, age, pregnancy plans, hypoglycemia history, and cost all factor in. See the treatment hub for more on options.
Side Effects and Monitoring
Every A1C medication has tradeoffs. Metformin can cause vitamin B12 deficiency with long-term use. Sulfonylureas and insulin can cause hypoglycemia. SGLT-2 inhibitors raise genital infection risk. GLP-1s slow gastric emptying enough to cause nausea and rare pancreatitis. Kidney function, liver function, A1C, and in some cases lactate levels should be checked at least once a year. Any new medication should trigger a home glucose log for the first two weeks to catch highs and lows.
The Bottom Line
A1C medication starts with metformin for most adults and escalates to GLP-1 agonists, SGLT-2 inhibitors, or insulin as needed. Expect a 0.5 to 1.5 point A1C drop from most single medications and 1.5 to 2.5 from the newest injectables. Combine medication with diet and exercise; alone, no drug can overcome an unchanged high-carbohydrate, sedentary lifestyle.
